Clinical Trials Logo

Clinical Trial Summary

The goal of this observational study is to evaluate the protective effect of immune barrier on secondary infection after COVID-19 (coronavirus disease 2019) vaccination or COVID-19 virus Omicron B A. 5.2 strain infection by dynamically monitoring the COVID-19 antibody titer, cellular immune function and the occurrence of secondary infection of healthy participants, mainly medical staff in our hospital, to understand the cross protective effect of COVID-19 antibody on different variants of Omicron, and explore the best time to use COVID-19 vaccine to strengthen immunity after Omicron mutant infection.

Clinical Trial Description

This study is a single center, prospective, non-intervention study. It is planned to recruit 300 medical and nursing participants, administrative and logistics participants or other participants who can cooperate with the follow-up for 48 weeks to voluntarily join the group. Participants will be investigated about the vaccination history of COVID-19 vaccine, whether they have ever been infected with COVID-19, the time of initial infection with COVID-19, and following clinical symptoms.The COVID-19 antibody titer of peripheral blood will be used for baseline. The participants will be divided into positive group and negative group according to the COVID-19 antibody titer results,then they wii be followed up for 48 weeks.If the participants have no symptoms related to COVID-19 infection, COVID-19 antibody and COVID-19 nucleic acid will be tested every 4-8 weeks according to the epidemic situation (the specific visit time is initially set as 0 week, 6 ± 2 weeks, 12 ± 4 weeks, 20 ± 4 weeks, 28 ± 4 weeks, 36 ± 4 weeks, 48 ± 4 weeks). There will be about 7 visits in total, according to the epidemic situation and the time of secondary infection of the participants). If the nucleic acid turns to be positive, we will consider it as the asymptomatic infection, then we will collect nasal/pharyngeal swabs for gene sequencing of virus strains, and terminate the study. If the participants get fever, fatigue, sore throat, cough, nasal congestion, runny nose, muscle soreness or headache and other symptoms related to COVID-19 infection during the study period, they need to test the COVID-19 antigen or COVID-19 nucleic acid within 48 hours. If it is positive, we will collect nasal/pharyngeal swabs for gene sequencing of virus strains, and terminate the study in advance. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05774093
Study type Observational
Source Sun Yat-sen University
Status Recruiting
Start date March 6, 2023
Completion date July 31, 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04997551 - Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19 Phase 3
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (COH04S1) Versus Emergency Use Authorization SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients With Blood Cancer Phase 2
Terminated NCT04455815 - A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) Phase 2
Completed NCT05049226 - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine Phase 2
Active, not recruiting NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Completed NCT04662437 - The Status of Parathyroid Hormone Secretion in Covid-19 Patients
Completed NCT04659200 - Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
Recruiting NCT04470583 - Evaluating Clinical Parameters of COVID-19 in Pregnancy
Withdrawn NCT04377568 - Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children Phase 2
Completed NCT04848610 - The Factors That Affect the Infection of COVID-19
Recruiting NCT04582903 - Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Terminated NCT04941703 - "CHANGE COVID-19 Severity" Phase 1/Phase 2
Recruiting NCT04639466 - A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19 Infection Phase 1
Completed NCT04575038 - CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 Phase 2
Recruiting NCT05022446 - The Impact of COVID-19 on Pulmonary Procedures
Active, not recruiting NCT04347798 - IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
Active, not recruiting NCT04650178 - Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
Active, not recruiting NCT04387656 - NCI COVID-19 in Cancer Patients, NCCAPS Study
Recruiting NCT04169542 - Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
Recruiting NCT04382781 - Immunosupressive Treatment in COVID-19 Patients